SCHEMBL3099475

SCHEMBL3099475

CC(Oc1cc2sc(NC(=O)NCCCO)nc2cc1F)c1c(Cl)ccc(F)c1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 5/20 0.47
MET P08581 13/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
KDR P35968 5/20 0.40
KDM4E B2RXH2 1/20 0.40
GLA P06280 1/20 0.40
FGFR2 P21802 2/20 0.39
AXL P30530 2/20 0.39
FLT3 P36888 2/20 0.39
MST1R Q04912 2/20 0.39
AURKA O14965 1/20 0.39
LCK P06239 1/20 0.39
FYN P06241 1/20 0.39
YES1 P07947 1/20 0.39
EPHA2 P29317 1/20 0.39
LTK P29376 1/20 0.39
PTK6 Q13882 1/20 0.39
SRC P12931 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3110077 0.95 ABL1 (0.45) ABL1METNPC1RAB9ASMN1; SMN2
SCHEMBL3109366 0.95 ABL1 (0.45) ABL1METNPC1RAB9ASMN1; SMN2
SCHEMBL3102528 0.93 MET (0.42) ABL1METNPC1RAB9ASMN1; SMN2
SCHEMBL3109379 0.93 MET (0.41) ABL1METNPC1RAB9ASMN1; SMN2
SCHEMBL3652242 0.93 MET (0.41) ABL1METNPC1RAB9ASMN1; SMN2
SCHEMBL3112125 0.92 MET (0.41) ABL1METNPC1RAB9ASMN1; SMN2
SCHEMBL3104496 0.92 MET (0.43) ABL1METKDRFGFR2AXL
SCHEMBL3097959 0.92 MET (0.43) ABL1METKDRFGFR2AXL
SCHEMBL3098297 0.92 MET (0.43) ABL1METKDRFGFR2AXL
SCHEMBL3102583 0.91 MET (0.42) ABL1METNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188078-B2 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as C-MET inhibitors SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS SANOFI-AVENTIS (FR) 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS MET, ALK, JAK2 ABL1 4/4885MET 1/4885NPC1 1581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.